Gelteq (GELS) Competitors $1.86 -0.25 (-11.85%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOwnershipSEC FilingsTrendsBuy This Stock GELS vs. GNLX, SLN, XBIT, ATOS, VOR, PLRX, ORMP, HLVX, OPTN, and ELUTShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Genelux (GNLX), Silence Therapeutics (SLN), XBiotech (XBIT), Atossa Therapeutics (ATOS), Vor Biopharma (VOR), Pliant Therapeutics (PLRX), Oramed Pharmaceuticals (ORMP), HilleVax (HLVX), OptiNose (OPTN), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Genelux Silence Therapeutics XBiotech Atossa Therapeutics Vor Biopharma Pliant Therapeutics Oramed Pharmaceuticals HilleVax OptiNose Elutia Genelux (NASDAQ:GNLX) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk. Does the media favor GNLX or GELS? In the previous week, Genelux and Genelux both had 1 articles in the media. Gelteq's average media sentiment score of 1.89 beat Genelux's score of 0.93 indicating that Gelteq is being referred to more favorably in the news media. Company Overall Sentiment Genelux Positive Gelteq Very Positive Does the MarketBeat Community prefer GNLX or GELS? Genelux received 16 more outperform votes than Gelteq when rated by MarketBeat users. CompanyUnderperformOutperformGeneluxOutperform Votes16100.00% Underperform VotesNo VotesGelteqN/AN/A Which has higher valuation & earnings, GNLX or GELS? Gelteq has lower revenue, but higher earnings than Genelux. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$8K10,467.71-$28.30M-$0.96-2.52GelteqN/AN/AN/AN/AN/A Do analysts recommend GNLX or GELS? Genelux presently has a consensus target price of $18.25, suggesting a potential upside of 654.13%. Given Genelux's stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of GNLX or GELS? 37.3% of Genelux shares are held by institutional investors. 9.3% of Genelux shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is GNLX or GELS more profitable? Gelteq's return on equity of 0.00% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -105.05% -80.16% Gelteq N/A N/A N/A SummaryGenelux beats Gelteq on 8 of the 11 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.56M$6.69B$5.47B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3222.5118.54Price / SalesN/A241.49397.62103.35Price / CashN/A65.8538.1834.62Price / BookN/A6.486.734.25Net IncomeN/A$143.41M$3.22B$248.18M7 Day Performance-19.83%2.30%1.58%1.25%1 Month Performance95.79%7.14%4.05%3.76%1 Year PerformanceN/A-2.61%15.75%5.28% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.86-11.8%N/AN/A$17.56MN/A0.00N/ALockup ExpirationPositive NewsGap DownGNLXGenelux1.6374 of 5 stars$2.90-1.4%$18.25+529.3%-13.5%$100.35M$8,000.00-3.0510Upcoming EarningsNews CoverageSLNSilence Therapeutics2.3501 of 5 stars$3.32+8.9%$40.67+1,124.9%-83.1%$99.37M$43.26M-2.11100News CoveragePositive NewsXBITXBiotech1.2668 of 5 stars$3.16+1.3%N/A-60.4%$96.34M$4.01M-2.93100News CoverageATOSAtossa Therapeutics1.9466 of 5 stars$0.74+11.2%$7.13+865.4%-40.5%$95.33MN/A-3.358Gap UpVORVor Biopharma2.2998 of 5 stars$0.76+8.4%$8.86+1,066.8%-60.5%$94.78MN/A-0.46140News CoveragePLRXPliant Therapeutics4.305 of 5 stars$1.54+2.7%$13.31+764.4%-86.5%$94.53M$1.58M-0.4690Upcoming EarningsNews CoveragePositive NewsORMPOramed Pharmaceuticals1.2259 of 5 stars$2.31+0.9%N/A+0.0%$94.36M$1.34M21.0010Upcoming EarningsHLVXHilleVax2.779 of 5 stars$1.86+4.5%$3.00+61.3%-85.3%$93.26MN/A-0.6020Upcoming EarningsNews CoveragePositive NewsOPTNOptiNose3.2589 of 5 stars$9.18+0.1%$9.00-2.0%-24.3%$92.97M$78.23M-2.19190Short Interest ↓News CoveragePositive NewsELUTElutia3.3059 of 5 stars$2.29+0.9%$9.00+293.0%-16.6%$92.47M$24.38M-0.88180Upcoming EarningsShort Interest ↑News CoverageGap Up Related Companies and Tools Related Companies Genelux Competitors Silence Therapeutics Competitors XBiotech Competitors Atossa Therapeutics Competitors Vor Biopharma Competitors Pliant Therapeutics Competitors Oramed Pharmaceuticals Competitors HilleVax Competitors OptiNose Competitors Elutia Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GELS Stock Free GELS Stock Alerts